Cooper-Standard Holdings Inc. Common Stock (CPS) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently positive earnings tone.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
54/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Medium
Headline depth
Last Price
$28.68
Trend Context
Mixed / range
Latest briefing
What's happening with CPS
prnewswire.com9 Jul 2026
Cooper Standard Earns Golden Scale Award for FlexiCore™ Technology
NORTHVILLE, Mich., July 9, 2026 /PRNewswire/ -- Cooper Standard (NYSE: CPS) was recently honored with the 2025 Golden Scale Award for Sealing System Innovation for its FlexiCore™ Thermoplastic Body Seal technology.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
gurufocus.com18 Jun 2026
The Empty Nest Is on Hold: 1 in 3 Adults Under 35 Lives With Their Parents, Realtor.com® Finds
The Empty Nest Is on Hold: 1 in 3 Adults Under 35 Lives With Their Parents, Realtor.com Finds PR Newswire AUST
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
prnewswire.com16 Jun 2026
Cooper Standard Recognized as a Finalist for IndustryWeek's Best Plants Awards
NORTHVILLE, Mich., June 16, 2026 /PRNewswire/ -- Cooper Standard's (NYSE: CPS) El Jarudo manufacturing facility in Juárez, Chihuahua, Mexico has been named one of only six finalists for IndustryWeek's 2026 Best Plants Awards for its world-class manufacturing practices.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
gurufocus.com
29 May 2026
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung